In vitro and in vivo antitumor efficacy of berberine-nanostructured lipid carriers against H22 tumor

Progress in Biomedical Optics and Imaging - Proceedings of SPIE

Volumn 9324, Issue , 2015, Pages

  Wang, Zhi Ping ^a   Wu, Jun Biao ^b   Chen, Tong Sheng ^c   Zhou, Qun ^d   Wang, Yi Fei ^e  

^a GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^b GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^c SOUTH CHINA NORMAL UNIVERSITY   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e JINAN UNIVERSITY   (China)

Author keywords

Antitumor activity; Berberine; H22 cells; Nanostructured lipid carriers; Tumor bearing mice

Indexed keywords

BIOCHEMISTRY; CHEMOTHERAPY; DISEASES; HOMOGENIZATION METHOD; IMMUNE SYSTEM; MAMMALS; PARTICLE SIZE; PHOTONICS; TUMORS;

ANTI-TUMOR ACTIVITIES; ANTI-TUMOR EFFICACY; BERBERINE; HIGH PRESSURE HOMOGENIZATION; INTRAGASTRIC ADMINISTRATION; NANOSTRUCTURED LIPID CARRIERS; ORAL BIOAVAILABILITIES; PHARMACOLOGICAL PROPERTIES;

DRUG PRODUCTS;

EID: 84928573725     PISSN: 16057422     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1117/12.2079107     Document Type: Conference Paper

References (24)

1. Parkin DM, "Global cancer statistics in the year 2000," Lancet Oncol, 2, 533-543 (2001).
2. Thomas MB, & Zhu AX, "Hepatocellular carcinoma: The need for progress," J Clinic Oncol, 23, 2892-2899 (2005).
3. Deng XK, Yin W, Li WD, Yin FZ, Lu XY, & Zhang XC, "The anti-tumor effects of alkaloids from the seeds of Strychnos nux-vomica on HepG2 cells and its possible mechanism," J Ethnopharmacol, 106, 179-186 (2006).
4. Liang M, Li SC, Shen B, Cai JP, Li C, Wang ZY, Li XG, Gao J, Huang HY, Zhang XY, & Li JY, "Anti-hepatocarcinoma effects of Aconitum coreanum polysaccharides," Carbohydrate Polymers, 88, 973-976 (2012).
5. Ikram M, "A review on the chemical and pharmacological aspects of genus berberis," Planta Med. 28, 353-358 (1975).
6. The Pharmacopoeia Commission of the People's Republic of China, "Pharmacopoeia of the People's Republic of China Part I," Beijing: China Medical Science Press, 13p, 79p, 285p (2010).
7. Iauk L, Costanzo R, Caccamo F, Rapisarda A, Musumeci R, & Milazzo I, "Activity of Berberis aetnensis root extracts on Candida strains," Fitoterapia, 78, 159-161 (2007).
8. Sun Y, Xun K, Wang Y, & Chen X, "A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs," Anticancer Drugs, 20, 757-769 (2009).
9. Tang J, Feng YB, Tsao SW, Wang N, Curtain R, & Wang YW, "Berberine and coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations," J Ethnopharmacol, 126: 5-17 (2009).
10. Qi HW, Xin LY, Xu X, Ji XX, & Fan LH, "Epithelial-to-mesenchymal transition markers to predict response of berberine in suppressing lung cancer invasion and metastasis," J Transl Med, 12: 22 (2014).
11. Yip NKY, & Ho WS, "Berberine induces apoptosis via the mitochondrial pathway in liver cancer cells," Oncol Rep, 30: 1107-1112 (2013).
12. Tan YL, Goh D, & Ong ES, "Investigation of differentially expressed proteins due to the inhibitory effects of berberine in human liver cancer cell line HepG2," Mol Biosyst, 2: 250-258 (2006).
13. Li Q, Zhang L, Zu Y, Liu T, Zhang B, & He W, "Generation of reactive oxygen species by a novel berberine-bile acid analog mediates apoptosis in hepatocarcinoma SMMC-7721 cells," Biochem Biophys Res Commun, 433: 432-437 (2013).
14. Yang X, & Huang N, "Berberine induces selective apoptosis through the AMPK-mediated mitochondrial/caspase pathway in hepatocellular carcinoma," Mol Med Rep, 8: 505-510 (2013).
15. Liu B, Wang GS, Yang J, Pan XD, Yang ZC, & Zang LQ, "Berberine inhibits human hepatoma cell invasion without cytotoxicity in healthy hepatocytes," Plos One, 6: e21416 (2011).
16. Ma C, Tang KL, Liu Q, Zhu RX, & Cao ZW, "Calmodulin as a potential target by which berberine induces cell cycle arrest in human hepatoma bel7402," Cells Chem Biol Drug Des, 81: 775-783 (2013).
17. Chen W, Miao YQ, Fan DJ, Yang SS, Lin X, Meng LK, & Tang X, "Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats," AAPS PharmSciTech, 12, 705-711 (2011).
18. Wang T, Wang N, Song H, Xi X, Wang J, Hao A, & Li T, "Preparation of an anhydrous reverse micelle delivery system to enhance oral bioavailability and anti-diabetic efficacy of berberine," Eur J Pharm Sci, 44, 127-135 (2011).
19. Zhu JX, Tang D, Feng L, Zheng ZG, Wang RS, Wu AG, Duan TT, He B, & Zhu Q, "Development of self-microemulsifying drug delivery system for oral bioavailability enhancement of berberine hydrochloride," Drug Dev Ind Pharm, 39: 499-506 (2013).
20. Zhang Y, Cui YL, Gao LN, & Jiang HL, "Effects of β-cyclodextrin on the intestinal absorption of berberine hydrochloride, a P-glycoprotein substrate," Int J Biol Macromol, 59, 363-371 (2013).
21. Doktorovova S, Souto EB, & Silva AM, "Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers - A systematic review of in vitro data," Eur J Pharm Biopharm, 87: 1-18 (2014).
22. Bondi ML, Azzolina A, Craparo EF, Botto C, Amore E, Giammona G, & Cervello M, "Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells," J Nanobiotech, 12: 21 (2014).
23. Wang ZP, & Chen TS, "Inhibitory efficacy of the quantified prunellae spica extract on H22 tumor bearing mice," Proc of SPIE, 8582, 85820S (2013).
24. Wang ZP, Wu JB, Zhou Q, Wang YF, & Chen TS, "Anti-hepatocarcinoma effects of berberine nanosuspension against human HepG2 and Huh7 cells as well as H22 tumor bearing mice," Proc of SPIE, 9230, 923003 (2014).